Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
A 77-year-old man presenting with episodic expressive aphasia
Neurol 90:e1822-e1826, Shanklin, A.,et al, 2018
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised
Neurol 79:2125-2132, Tan, L.,et al, 2012
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008